CBD Science Group is delighted to confirm that its Real World Evidence (RWE) study has been approved by the Living With and Beyond Cancer (LWBC) Executive Group of the National Cancer Research Institute (NCRI).
LONDON, September 2, 2021 / PRNewswire / – CBD Science Group (the ‘Society‘) is delighted to announce a much sought-after endorsement from the National Cancer Research Institute (NCRI), which saw the NCRI Living With and Beyond Cancer (LWBC) executive group endorse the Real World Evidence (RWE) study about the role cannabinoids can play in treating cancer pain. The development will give hope to cancer patients around the world, as the treatment and management of cancer pain continues to be a major burden on patients and their families.
CBD Science Group is a biopharmaceutical company that enables accelerated access to treatment through a pragmatic, peer-reviewed Real World Evidence clinical trial. This aims to quickly deliver nationally approved therapies to patients with already developed trial protocols and ongoing patient recruitment ahead of a start date in Q2 2022.
âWe are delighted and proud to have received this approval from the NCRI LWBC, which offers hope to millions of people with long-term cancer pain around the world. This partnership will advance the CBD Science Group towards our goal of realizing the benefits of cannabinoids. to meet this urgent need of suffering patients. We strongly believe in the opportunity presented by our RWE study, and we look forward to working closely and deepening our relationship with the NCRI “
Graeme McFarlane, Commercial Director, CBD Science Group.
The company has appointed a Distinguished Clinical Advisory Board under the leadership of the Group Chief Clinical Advisor and former Deputy Medical Director of Professor NHS England Mike Bewick with other leading experts in space, including the professor Sam Ahmedzai.
âPrevious cancer pain research focused on people with advanced disease, but there is a large and rapidly growing population of people who survive for many years with cancer. The reality is that chronic pain associated with cancer itself, or resulting from anti-cancer treatments, is an insurmountable barrier to a productive and fulfilling life with family and friends – at all stages of cancer. Unfortunately, current pain treatment options are largely ineffective or cause even more harmful side effects; therefore, more research is urgently needed to find better therapies. I am delighted to be an active participant in the CBD Science Group’s goal of finding an effective and safer medicinal cannabis solution to alleviate the suffering of patients living with cancer-related pain.
Emeritus professor Sam Ahmedzai, co-chair of the Living with and beyond cancer research group at the NCRI
NICE guidelines on medical cannabis found that previous evidence for chronic pain associated with cancer patients was lacking, making research into the use of cannabinoids as an alternative pain medication extremely timely. Also given the lack of evidence to prove efficacy and significant evidence showing the long-term harm caused by opioids, the National Institute for Health and Care Excellence (NICE) has recommended against using opioids for sufferers. chronic primary pain and actively encourages the search for alternative solutions.
On top of that, the continued fallout from COVID -19 affects oncologists and clinicians across the UK. It has been reported that the UK is experiencing an emerging cancer crisis after new figures recently showed more than 300,000 people had missed disease controls since the start of the pandemic. Fears that more patients than ever will not be treated for their cancer and opioid prescriptions will continue to soar as suitable alternatives are still not available through the NHS.
In the United Kingdom, it is estimated 3 million cancer patients with 367,000 new diagnoses per year. In this population, the prevalence of pain has been shown to affect 39.3% after curative treatment; 55.0% during cancer treatment; and 66.4% in case of advanced, metastatic or terminal disease. With millions of patients untreated for cancer-related pain, it is clear that there is an urgent need to prove that cannabis-based drugs are an alternative for effective pain treatments.
This press release may contain certain âforward-looking informationâ and âforward-looking statementsâ within the meaning of applicable securities laws. All information contained in this document that is not historical in nature may constitute forward-looking information. CBD Science Group assumes no obligation to comment on any analyzes, expectations or statements made by third parties regarding CBD Science Group, its titles or its financial or operational results (if any). Although CBD Science Group believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements have been based on expectations, factors and assumptions regarding future events which may prove to be inaccurate and are subject to at many risks. and uncertainties, some of which are beyond the control of CBD Science Group. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. CBD Science Group disclaims any intention and has no obligation or liability, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. .
Contact for inquiry:
E: [email protected]
T: +44 7734256318
View original content to download multimedia:https://www.prnewswire.com/news-releases/national-cancer-research-institute-endorses-cbd-science-group-as-they-pioneer-real-world-research-into-cancer-pain-301367496. html
SOURCE CBD Science Group PLC